WEST LAFAYETTE, Ind., Nov. 10, 2021 (GLOBE NEWSWIRE) -- November 10, 2021 -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the opening of its newly-constructed, scientific laboratories at its St. Louis facility with operations focused on supporting clients in the areas of drug metabolism & pharmacokinetics (DMPK), cell & molecular biology, pharmacology, toxicology and histopathology.
“The new, state-of-the-art DMPK and cell & molecular biology laboratories, archives, and offices expands our capabilities to support clients from the earliest of drug discovery stages through clinical development,” said Scott Daniels, Sr. Vice President and Site Lead of Operations. “Moreover, concurrent investments in science and technology to outfit this new construction, including upgraded mass spectrometry, flow cytometry and gene profiling platforms, effectively extends our coverage of the therapeutic landscape to include novel biotherapeutics, ranging from oligonucleotides and proteins to gene therapies.”
The completed project also includes expanded histology laboratory and archiving space to accommodate growth in Inotiv’s pathology business that has resulted from recent increases in the discovery pharmacology footprint, as well as increased demand in development stage toxicology.
“These expanded capabilities to serve our clients come at an ideal time, particularly given the recent Envigo acquisition and increases in our in vivo pharmacology operations,” said John Sagartz, Inotiv’s Chief Strategy Officer. “Increased demand for specialty disease pharmacology and transgenic models coincides with a need for broad laboratory sciences and associated expertise. The opening of these newly-constructed laboratories is perfectly timed with our expanded drug discovery and development services at Inotiv.”
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
